Similarly, cyst fluid analysis in IPMN patients shows variable positivity rates, ranging from 26% to 82% for KRAS and 27% to 66% for GNAS mutations [17, 30, 31, 32, 33, 34]. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.